Katherine T. Murray

Dr. Katherine T. Murray


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2024 in EP Europace
Verified
Journal Article
Open access
PDF file
Andreas GoetteAndreas Goette
Andreas Goette
DCDomenico Corradi
Domenico Corradi
DDDobromir Dobrev
Dobromir Dobrev
LALuis Aguinaga
Luis Aguinaga
JCJosé Ángel Cabrera
José Ángel Cabrera
RTRicardo Alkmim Teixeira
Ricardo Alkmim Teixeira
Aims: The concept of “atrial cardiomyopathy” (AtCM) had been percolating through the literature since its first mention in 1972. Since then, publications using the term were sporadic until the decision was made to convene an expert working group with representation from four multinational arrhythmia organizations to prepare a consensus document on atrial cardiomyopathy in 2016 (EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication). Subsequently, publications on AtCM have increased progressively. Methods and results: The present consensus document elaborates the 2016 AtCM document further to implement a simple AtCM staging system (AtCM stages 1–3) by integrating biomarkers, atrial geometry, and electrophysiological changes. However, the proposed AtCM staging needs clinical validation. Importantly, it is clearly stated that the presence of AtCM might serve as a substrate for the development of atrial fibrillation (AF) and AF may accelerates AtCM substantially, but AtCM per se needs to be viewed as a separate entity. Conclusion: Thus, the present document serves as a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS) to contribute to the evolution of the AtCM concept.

20 September 2002 in Circulation Research
Verified
Journal Article
Closed access
PDF file
JZJingsong Zhou
Jingsong Zhou
HSHyeon-Gyu Shin
Hyeon-Gyu Shin
JYJianxun Yi
Jianxun Yi
WSWangzhen Shen
Wangzhen Shen
CWChristine P. Williams
Christine P. Williams
KMKatherine T. Murray
Katherine T. Murray
Activation of protein kinase A (PKA) increases Na + current derived from the human cardiac Na + channel, hH1, in a slow, nonsaturable manner. This effect is prevented by compounds that disrupt plasma membrane recycling, implying enhanced trafficking of channels to the cell membrane as the mechanism responsible for Na + current potentiation. To investigate the molecular basis of this effect, preferred consensus sites (serines 483, 571, and 593) and alternative sites phosphorylated by PKA in the rat heart isoform (serines 525 and 528) were removed in the I-II interdomain linker, a region in the channel previously implicated in the PKA response. Our results demonstrate that the presence of either serine 525 or 528 is required for Na + current potentiation. The role of amino acid sequences that can mediate channel-protein interactions was also examined. Removal of a PDZ domain-binding motif at the carboxy terminus of hH1 did not alter the PKA response. The I-II interdomain linker of the channel contains 3 sites (479RKR481, 533RRR535, and 659RQR661) with the sequence RXR, a motif known to mediate retention of proteins in the endoplasmic reticulum (ER). The PKA-mediated increase in Na + current was abolished when all 3 sites were eliminated, with RRR at position 533 to 535 primarily responsible for this effect. These results demonstrate that both α-subunit phosphorylation and the presence of putative ER retention signals are required for the PKA-mediated increase in cardiac Na + current, an effect that likely involves interaction of the I-II interdomain linker with other proteins or regions of the channel.

1 April 2017 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
ZYZhenjiang Yang
Zhenjiang Yang
JPJoseph K. Prinsen
Joseph K. Prinsen
KBKevin R. Bersell
Kevin R. Bersell
WSWangzhen Shen
Wangzhen Shen
LYLiudmila Yermalitskaya
Liudmila Yermalitskaya
KMKatherine T. Murray
Katherine T. Murray
Background—: The widely used macrolide antibiotic azithromycin increases risk of cardiovascular and sudden cardiac death, although the underlying mechanisms are unclear. Case reports, including the one we document here, demonstrate that azithromycin can cause rapid, polymorphic ventricular tachycardia in the absence of QT prolongation, indicating a novel proarrhythmic syndrome. We investigated the electrophysiological effects of azithromycin in vivo and in vitro using mice, cardiomyocytes, and human ion channels heterologously expressed in human embryonic kidney (HEK 293) and Chinese hamster ovary (CHO) cells. Methods and Results—: In conscious telemetered mice, acute intraperitoneal and oral administration of azithromycin caused effects consistent with multi-ion channel block, with significant sinus slowing and increased PR, QRS, QT, and QTc intervals, as seen with azithromycin overdose. Similarly, in HL-1 cardiomyocytes, the drug slowed sinus automaticity, reduced phase 0 upstroke slope, and prolonged action potential duration. Acute exposure to azithromycin reduced peak SCN5A currents in HEK cells (IC 50 =110±3 μmol/L) and Na + current in mouse ventricular myocytes. However, with chronic (24 hour) exposure, azithromycin caused a ≈2-fold increase in both peak and late SCN5A currents, with findings confirmed for I Na in cardiomyocytes. Mild block occurred for K + currents representing I Kr (CHO cells expressing hERG; IC 50 =219±21 μmol/L) and I Ks (CHO cells expressing KCNQ1+KCNE1; IC 50 =184±12 μmol/L), whereas azithromycin suppressed L-type Ca ++ currents (rabbit ventricular myocytes, IC 50 =66.5±4 μmol/L) and I K1 (HEK cells expressing Kir2.1, IC 50 =44±3 μmol/L). Conclusions—: Chronic exposure to azithromycin increases cardiac Na + current to promote intracellular Na + loading, providing a potential mechanistic basis for the novel form of proarrhythmia seen with this macrolide antibiotic.

1 October 2009 in Journal of Molecular and Cellular Cardiology
Verified
Journal Article
Closed access
LMLisa C. Mace
Lisa C. Mace
LYLiudmila V. Yermalitskaya
Liudmila V. Yermalitskaya
YYYajun Yi
Yajun Yi
ZYZhenjiang Yang
Zhenjiang Yang
AMAshley M. Morgan
Ashley M. Morgan
KMKatherine T. Murray
Katherine T. Murray

21 October 2022 in American Journal of Physiology-Heart and Circulatory Physiology
Verified
Journal Article
Open access
PDF file
CRCrystal M. Ripplinger
Crystal M. Ripplinger
AGAlexey Glukhov
Alexey Glukhov
MKMatthew Wyatt Kay
Matthew Wyatt Kay
BBBastiaan J. Boukens
Bastiaan J. Boukens
NCNipavan Chiamvimonvat
Nipavan Chiamvimonvat
NPNikki G. Posnack
Nikki G. Posnack
Cardiac arrhythmias are a major cause of morbidity and mortality worldwide. Although recent advances in cell-based models, including human-induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM), are contributing to our understanding of electrophysiology and arrhythmia mechanisms, preclinical animal studies of cardiovascular disease remain a mainstay. Over the past several decades, animal models of cardiovascular disease have advanced our understanding of pathological remodeling, arrhythmia mechanisms, and drug effects and have led to major improvements in pacing and defibrillation therapies. There exist a variety of methodological approaches for the assessment of cardiac electrophysiology and a plethora of parameters may be assessed with each approach. This guidelines article will provide an overview of the strengths and limitations of several common techniques used to assess electrophysiology and arrhythmia mechanisms at the whole animal, whole heart, and tissue level with a focus on small animal models. We also define key electrophysiological parameters that should be assessed, along with their physiological underpinnings, and the best methods with which to assess these parameters. Listen to this article’s corresponding podcast at https://ajpheart.podbean.com/e/guidelines-for-cardiac-electrophysiology/ .

1 December 2004 in Heart Rhythm
Verified
Journal Article
Closed access
KMKatherine T. Murray
Katherine T. Murray
JRJeffrey N. Rottman
Jeffrey N. Rottman
PAPatrick G. Arbogast
Patrick G. Arbogast
LSLynn Shemanski
Lynn Shemanski
RPR. Kirby Primm
R. Kirby Primm
WRWayne A. Ray
Wayne A. Ray